|
|
Post by mnkdnewbie on Jan 4, 2016 12:48:58 GMT -5
they updated the trial on 10/19/2015: Feasibility Study using Zone-MPPC controller, HMS and Technosphere Insulin Inhalation System from MannKind Corp, with a citation.
www.ncbi.nlm.nih.gov/pubmed/25901023
Conclusion: Adding preprandial Tl (see video supplement) to an automated closed-loop AP system resulted in superior postprandial control as demonstrated by lower postprandial glucose exposure without addition hypoglycemia.
Maybe this has been mentioned before and I missed it. |
|
|
|
Post by grandpoobah on Jan 4, 2016 14:30:03 GMT -5
they updated the trial on 10/19/2015: Feasibility Study using Zone-MPPC controller, HMS and Technosphere Insulin Inhalation System from MannKind Corp, with a citation.
www.ncbi.nlm.nih.gov/pubmed/25901023
Conclusion: Adding preprandial Tl (see video supplement) to an automated closed-loop AP system resulted in superior postprandial control as demonstrated by lower postprandial glucose exposure without addition hypoglycemia.
Maybe this has been mentioned before and I missed it. I remember reading that abstract. Unfortunately, the full paper costs quite a bit to read. I noticed that, unlike many pharma companies, MNKD doesn't appear to maintain an accessible library of afrezza relevant publications. Why is that? It might help to make the data readily available for those interested. |
|
|
|
Post by peppy on Jan 4, 2016 18:28:02 GMT -5
they updated the trial on 10/19/2015: Feasibility Study using Zone-MPPC controller, HMS and Technosphere Insulin Inhalation System from MannKind Corp, with a citation.
www.ncbi.nlm.nih.gov/pubmed/25901023
Conclusion: Adding preprandial Tl (see video supplement) to an automated closed-loop AP system resulted in superior postprandial control as demonstrated by lower postprandial glucose exposure without addition hypoglycemia.
Maybe this has been mentioned before and I missed it. Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. screencast.com/t/EToFHdyd A study talking about Afrezza and first phase insulin response. screencast.com/t/ZaphFSR2qYT5 Subq fast acting analogues do NOT mimic first phase insulin response.
Nice study.
|
|
|
|
Post by grandpoobah on Jan 5, 2016 1:03:59 GMT -5
they updated the trial on 10/19/2015: Feasibility Study using Zone-MPPC controller, HMS and Technosphere Insulin Inhalation System from MannKind Corp, with a citation.
www.ncbi.nlm.nih.gov/pubmed/25901023
Conclusion: Adding preprandial Tl (see video supplement) to an automated closed-loop AP system resulted in superior postprandial control as demonstrated by lower postprandial glucose exposure without addition hypoglycemia.
Maybe this has been mentioned before and I missed it. Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. screencast.com/t/EToFHdyd A study talking about Afrezza and first phase insulin response. screencast.com/t/ZaphFSR2qYT5 Subq fast acting analogues do NOT mimic first phase insulin response.
Nice study.
Lispro, a fast acting analogue, does appear to mimic afrezza's initial effects:  For all practical purposes, the effect on blood glucose for the first 60 minutes are identical. |
|
|
|
Post by mnholdem on Jan 5, 2016 8:30:54 GMT -5
In separate but somewhat related news, one of Al Mann's other companies, Medallion Therapeutics, is scheduled to complete ClinicalTrials.gov Identifier NCT01185470 "The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain" sometime in June 2016.
clinicaltrials.gov/ct2/show/record/NCT01185470?term=medallion+therapeutics&rank=1
The current FDA trial is testing the accuracy of the implantable smart pump for delivering morphine for patients with cancer and/or chronic pain, but it's been stated in previous articles that this programmable infusion pump can use MannKind's proprietary Technosphere technology to deliver any number of API, including insulin. NCT01185470 has been a 5-year study.
"The Medallion Therapeutics product line is based on novel implantable drug delivery infusion pump developed by AMF scientists and engineers to provide superior safety, connectivity and large molecule infusion capabilities. These capabilities address both the requirements of currently approved clinical indications, as well as enable future expansion into new indications in areas such as diabetes and neurodegenerative disease. Medallion Therapeutics is the result of over 10 years of research and development to create the novel Medallion implantable drug delivery system. The company is currently conducting a pivotal clinical evaluation in the United States to support an upcoming submission for pre-market approval (PMA), as well as pursuing CE Mark certification to support distribution in Europe."
Link: www.businesswire.com/news/home/20140305005467/en/Alfred-Mann-Foundation-Scientific-Research-Creates-Medical
|
|
|
|
Post by esstan2001 on Jan 5, 2016 8:39:01 GMT -5
For all practical purposes, the effect on blood glucose for the first 60 minutes are identical. In my reading of the curves, Afrezza's sharp rise occurs 10-15 minutes earlier than Lispro; Afrezza's rise is over at about 30 minutes, Lispro's at 45 minutes. Past that, Afrezza takes out serious area under the Lispro curve, indicating a dramatic difference (cut) in glucose infusion rate. In no way do I see the curves as being identical for the first 60 minutes. Maybe an expanded scale for the X axis would help to clarify this :-) |
|
|
|
Post by peppy on Jan 5, 2016 8:42:21 GMT -5
Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. screencast.com/t/EToFHdyd A study talking about Afrezza and first phase insulin response. screencast.com/t/ZaphFSR2qYT5 Subq fast acting analogues do NOT mimic first phase insulin response.
Nice study.
Lispro, a fast acting analogue, does appear to mimic afrezza's initial effects: For all practical purposes, the effect on blood glucose for the first 60 minutes are identical. Oh ha ha, I can produce a chart for everyone that you through up. Sometimes email is much more efficient than snail mail. screencast.com/t/ZaphFSR2qYT5
quote: Lispro, a fast acting analogue, does appear to mimic afrezza's initial effects: reply: appearances can be deceptive. screencast.com/t/ZaphFSR2qYT5 screencast.com/t/bGSOtyTqp7L1
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 8:49:49 GMT -5
Lispro, a fast acting analogue, does appear to mimic afrezza's initial effects: For all practical purposes, the effect on blood glucose for the first 60 minutes are identical. Oh ha ha, I can produce a chart for everyone that you through up. Sometimes email is much more efficient than snail mail. screencast.com/t/ZaphFSR2qYT5
quote: Lispro, a fast acting analogue, does appear to mimic afrezza's initial effects: reply: appearances can be deceptive. screencast.com/t/ZaphFSR2qYT5 screencast.com/t/bGSOtyTqp7L1
grandpoobah is a troll.. i think most here have figured it out |
|
